<DOC>
	<DOCNO>NCT00724711</DOCNO>
	<brief_summary>This protocol describe prospective , randomize , open-label , multicenter study evaluate safety efficacy switch fix dose abacavir ( ABC ) /lamivudine ( 3TC ) fix dose emtricitabine ( FTC ) /tenofovir disoproxil fumarate ( TDF ) virologically suppress , human immunodeficiency virus type 1 ( HIV-1 ) infect subject maintain ritonavir-boosted protease inhibitor ( PI/r ) -containing antiretroviral ( ARV ) regimen . Duration treatment 48 week .</brief_summary>
	<brief_title>Safety Efficacy Study Switching From Epzicom Truvada</brief_title>
	<detailed_description>This protocol describe prospective , randomize , open-label , multicenter study evaluate safety efficacy switch fix dose ABC/3TC fix dose FTC/TDF virologically suppress , HIV-1 infect subject maintain PI/r-containing ARV regimen . Subjects stratify base PI/r ( ie , lopinavir/ritonavir [ LPV/r ] versus boost PIs ) regimen , presence versus absence comorbidities screen ( diabetes mellitus cardiovascular disease hypertension , coronary artery disease , hyperlipidemia , history myocardial infarction , cardiomyopathy , valvular heart disease , congenital heart disease , stroke , peripheral vascular disease , arrhythmia ) . Subjects randomized 1:1 switch FTC/TDF+PI/r continue exist regimen . Subjects receive study treatment 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Adult ( great equal 18 year ) male nonpregnant , nonlactating female HIV1 infect subject currently receive ritonavirboosted protease inhibitor fixeddose ABC/3TC regimen continuously great equal 3 month HIV infection document validated HIV antibody enzymelinked immunosorbent assay ( ELISA ) confirm one following : Immunoblot detection HIV antibody Positive HIV1 blood culture Positive HIV1 serum P24 antigen HIV1 plasma viremia great 1000 copies/mL polymerase chain reaction ( PCR ) branchedchain deoxyribonucleic acid ( bDNA ) method Detection proviral DNA PCR ( If confirmation HIV infection available repeat test HIV antibody require ) Two consecutive plasma HIV1 RNA concentration le 200 copies/mL . The two HIV1 RNA determination ensure subject virologicallysuppressed least 3 month prior study entry : The subject must plasma HIV1 RNA level le 200 copies/mL use AmpliPrep/Taqman HIV1 Test Roche Amplicor HIV1 Monitor Test Version 1.5 Ultrasensitive method least 3 month prior screen visit , `` qualify HIV1 RNA . '' HIV1 RNA le 200 copies/mL measure bDNA ( Chiron 3.0 ) may use qualify HIV1 RNA entry study confirmatory HIV1 RNA . The subject must confirm second plasma HIV1 RNA le 200 copies/mL screening , `` confirmatory HIV1 RNA . '' The subject must plasma HIV1 RNA great equal 200 copies/mL qualify confirmatory HIV1 RNA measurement . Subjects receive lipidlowering agent ( LLA ) allow ; however , LLAs must stable great equal 3 month prior study entry . Adequate renal function define calculated CLcr great equal 50 mL/min accord CockcroftGault formula Negative serum pregnancy test ( female childbearing potential ) Hepatic transaminase alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less equal 5 X upper limit normal Males female ( childbearing potential , ie , nonmenopausal female female menopause &lt; 2 year , hysterectomy , bilateral oophorectomy , medically document ovarian failure ; definition include young woman yet start menstruate ) , must agree avoid pregnancy sexual abstinence , utilization highly effective method birth control throughout study period 30 day follow discontinuation study drug The ability understand sign write informed consent form , must obtain prior initiation study procedure Subjects receive ABC/3TC PI without ritonavir Subjects receive ARV agent ( eg , 2 protease inhibitor boost lowdose ritonavir ( ie , `` doubleboosted PI regimen '' ) , nonnucleoside reverse transcriptase inhibitor [ NNRTIs ] , integrase inhibitor , TDF , nucleoside reverse transcriptase inhibitor [ NRTIs ] ) addition ABC/3TC ritonavirboosted protease inhibitor Have know resistance study agent time past include NRTI resistance mutation ( include limit K65R , L74V/I , M184V/I , thymidine analog mutation ) and/or PI resistance mutation A new acquire immunodeficiency syndrome ( AIDS ) define condition diagnose ( exception CD4 criterion ) within 30 day baseline Previous therapy agent systemic myelosuppressive , pancreatoxic , hepatotoxic cytotoxic potential within 3 month study start expect need therapy time enrollment Proven suspect acute hepatitis 30 day prior study entry Anticipated need initiate drug study contraindicate protease inhibitor ( except upon approval Gilead ) Receiving ongoing therapy follow ( administration follow medication must discontinue least 30 day prior Baseline visit duration study period ) : Nephrotoxic agent ( aminoglycoside antibiotic , amphotericin B , cidofovir , cisplatin , foscarnet , intravenous pentamidine , agent significant nephrotoxic potential ) Adefovir dipivoxil Probenecid Systemic chemotherapeutic agent ( ie , cancer treatment medication ) Systemic corticosteroid Interleukin2 ( IL2 ) Investigational agent ( except upon approval Gilead ) Pregnant lactate subject Evidence gastrointestinal malabsorption syndrome chronic nausea vomiting may confer inability receive orally administer medication Current alcohol substance abuse judge investigator potentially interfere subject adherence Malignancy cutaneous Kaposi 's sarcoma ( KS ) basal cell carcinoma . Subjects biopsyconfirmed cutaneous KS eligible , must receive systemic therapy KS within 30 day baseline anticipate require systemic therapy study . Active , serious infection ( HIV1 infection ) require parenteral antimicrobial therapy within 15 day prior screen Prior history significant renal bone disease Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study unable comply dose requirement Known hypersensitivity study drug , metabolite formulation excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV 1</keyword>
</DOC>